The growing interest in potent weight management has resulted in considerable exploration into novel treatments. Currently, Retatrutide, a combined -action glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor activator , has exhibited encouraging results in patient trials, suggesting potential for significant weight loss . As a res